T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
A Phase 1 / 2 Single Arm Study of T-cells Expressing Anti-CD19 Chimeric Antigen Receptor in Pediatric and Young Adult Patients With B-cell Malignancies
Sponsor: Sheba Medical Center
This PHASE1/PHASE2 trial investigates Acute Lymphoblastic Leukemia, B-precursor and Non-Hodgkin Lymphoma, B-cell and is currently ongoing. Sheba Medical Center leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2022 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Dec 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Unknown Status → Recruiting
▶ Show 4 earlier versions
-
May 2020 — Dec 2020 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — May 2020 [monthly]
Recruiting PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — May 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sheba Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .